Will Genentech Embrace PGx in Appeal of FDA Decision to Revoke Approval of Avastin in Breast Cancer? | GenomeWeb

Originally published Dec. 17.

By Turna Ray

Genentech said this week that it plans to request a hearing to maintain Avastin as a treatment option for metastatic breast cancer following the US Food and Drug Administration's recommendation to withdraw its approval of the drug for that indication.

The Roche subsidiary has 15 days from Dec. 16 to request the hearing, and noted that if the agency grants the request, "there is no set date for when this would occur."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: peanut subgenome progenitor sequence, homozygosity mapping and linkage analyses using exome data, and more.

Tech companies like Microsoft are looking into DNA as a data storage device, Scientific American writes.

The New York Times writes that the Max Planck Institute for Infection Biology's Emmanuelle Charpentier has always been on the move, though now it's more about CRISPR.

The European Union calls for all publicly funded scientific papers to be immediately freely accessible to the public by 2020.